Peptide Cancer Vaccine Market

In 2022, the global market for peptide cancer vaccines reached a valuation of US$4.44 billion and is expected to experience a significant growth rate in the coming years.

Market Overview

The global market for peptide cancer vaccines is valued at $4.44 billion as of 2022. The market shows potential for growth, with a projected valuation of $10.31 billion by the year 2030. The anticipated compound annual growth rate (CAGR) is expected to be around 11.10% for the projection period (2022 through 2028).

Peptide Cancer Vaccines play a very important role in stimulating and enhancing the development of T-lymphocytes specific to tumors. This allows for the control or elimination of said tumors.

The vaccines consist of sequences of amino acids, which can be short or long. These amino acids act as tumor antigens combined with a vaccine adjuvant, that creates a stronger immune response in people who receive the vaccine.

Clinical trials focused on peptide cancer vaccines have brought about unsatisfactory outcomes. As a result, researchers considered this approach to be outdated and ineffective when it comes to cancer treatment. However, the work towards vaccine research doesn’t end here.

The advancements in technology have led to a greater understanding of vaccine adjuvants relating to immunology and vaccine administration techniques. By understanding this and how T-cells work, the use of vaccines for treating malignant diseases like cancer has returned as a priority for researchers.

The market is segmented using three criteria:

• Application: Breast Cancer, Lung Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others
• Type: Personalized Peptide, Peptide Cocktail Type, Multivalent Peptide, Peptide Pulsed Dendritic Cancer, Other
• Technology: Recombinant Cancer, Viral Vector & DNA Cancer, Whole-cell Cancer, Dendritic Cells, Antigens, Other

Key Report Findings

• In 2022, the peptide cancer vaccine market stood at an approximate USD $4.44 billion
• The market is expected to grow at a rate of 11.10% to USD $10.31 billion by 2030.
• The peptide-pulsed dendritic cancer vaccine segment has the largest market share over the forecast period, and is likely to remain so.
• In terms of application, the prostate cancer and breast cancer segments have dominated the market
• The market is mainly driven due to the cost-effectiveness of vaccine production, and the advancements in immunotherapy research.
• The increased risk of cancer creates opportunities for the market, due to the need for treatments.
• The growing demand for personalized medicine also creates opportunities for the peptide cancer vaccination market.
• Accessibility to vaccinations in remote areas, as well as the shortage of storage space creates challenges
• The Asian market is the fastest growing due to the increasing prevalence of cancer in growing populations

Market Drivers

Cost Effective Use & Production

The peptide cancer vaccine market anticipates significant growth in the coming years. One of the reasons for this is the convenience with which the vaccines are synthesized and prepared. Production is cost-effective, and their application in clinical settings results in an increase in use.

The flexibility with which antigens can be changed and the reduced risk of antigen-induced anaphylaxis also results in the use of vaccines becoming safer and more convenient.

As a result, research and development in the field of peptide cancer vaccines is becoming a priority for manufacturers.

Advancements in Immunotherapy Research

As immunotherapy research advances and understanding of T-cell dynamics increases, the production of vaccines also increases. Novel adjuvants are being developed and are used for progressing peptide vaccine technologies.

A key area of advancement is the discovery of tumor-specific antigens. Researchers have identified a wide range of antigens that are specifically expressed on cancer cells. This makes them ideal targets for immune-based therapies.

Peptide cancer vaccines leverage this knowledge by utilizing short or long amino acid sequences as tumor antigens, stimulating the immune system to recognize and attack cancer cells.

These advancements create opportunities for developing more effective and efficient peptide cancer vaccines.

The acceleration of telemedicine and digital healthcare due to the COVID-19 pandemic also improved efficiency of cancer vaccines.

Market Opportunities

Increasing Risk of Cancer

The increasing prevalence of cancer and the inadequacy of conventional cancer treatments in effectively addressing the disease have fueled the demand for innovative immunotherapy-based therapeutics like Peptide Cancer Vaccines.

Research from the National Cancer Institute states that there were 16.8 million new cancer cases in 2016. This resulted in close to 600,000 deaths. Cancer is still one of the leading causes of death today, and the number of people diagnosed with cancer is projected to reach approximately 19 million within the next year.

The WHO recorded about 14 million cases of cancer in 2012. The surge in cancer cases has increased the demand for peptide vaccines significantly, and thus has contributed towards the growth of the market itself.

Growing Demand for Personalized Medicine

The growing demand for personalized medicine has emerged as a significant driver for the expansion of the market. Personalized medicine tailors treatment strategies to individual patients based on their unique characteristics. This includes genetic makeup, tumor profile and immune response.

This allows peptide cancer vaccines to target specific tumor antigens. Because every patient’s cancer is unique, the ability to target specific tumor antigens enhances the immune system. It can recognize and attack cancer cells while minimizing the damage caused to healthy tissue.

By focusing on individualized targets, peptide cancer vaccines have the potential to achieve higher treatment efficacy and better patient responses.

Market Challenges

Accessibility to Vaccinations & Storage

The lack of accessibility to cancer vaccinations in remote areas hampers the overall market growth. Additionally, the requirement for safe storage and transportation poses challenges to the widespread distribution of Peptide Cancer Vaccines.

Despite these limitations, there are several factors that indicate promising growth prospects for the market. Increasing public awareness about cancer diseases plays a significant role in driving the demand for cancer vaccines. Moreover, both government and private sector investments in research and development contribute to the advancement of Peptide Cancer Vaccines.

Regional Coverage

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

The North American market has the largest market share, and is also the fastest growing. High prevalence of cancer in heavily populated areas in Asia, such as China and India, also suggests that there will be significant market growth in these regions.

Company Recent Development 

Some of the major players in the peptide cancer vaccine market include:

• TapImmune (US)
• VAXON Biotech
• BrightPath Biotherapeutics
• Boston Biomedical
• Sellas
• Merck
• Biolife Science

ISA Pharmaceuticals presented valuable insights into cancer vaccine development during an educational session held at the ESMO Immuno-Oncology Congress 2021, which took place in December 2021. This session shed light on important learnings in the field of cancer vaccine research and development.

A phase 1 clinical trial was conducted in patients with advanced malignancy by Boston Biomedical Inc. in 2019. The study was focused on evaluating DSP-7888, which is an investigational WT1 cancer peptide vaccine. The presentation of these new results provided valuable information regarding the potential of DSP-7888 as a therapeutic option for advanced cancer cases.